Life Science

A lipopeptide antibiotic effective against resistant Gram-positive bacteria (MIC90s range from 0.25-16 mg/L) alters bacterial plasma membrane potential and redirects the binding of proteins essential for cell division and cell wall synthesis.

A lipopeptide antibiotic effective against resistant Gram-positive bacteria (MIC90s range from 0.25-16 mg/L) alters bacterial plasma membrane potential and redirects the binding of proteins essential for cell division and cell wall synthesis.

A lipopeptide antibiotic effective against resistant Gram-positive bacteria (MIC90s range from 0.25-16 mg/L) alters bacterial plasma membrane potential and redirects the binding of proteins essential for cell division and cell wall synthesis.

A reversible inhibitor of Lp-PLA2 (IC₅₀ = 0.25 nM) that produces sustained inhibition of plasma Lp-PLA2 activity in humans.

A reversible inhibitor of Lp-PLA2 (IC₅₀ = 0.25 nM) that produces sustained inhibition of plasma Lp-PLA2 activity in humans.

A reversible inhibitor of Lp-PLA2 (IC₅₀ = 0.25 nM) that produces sustained inhibition of plasma Lp-PLA2 activity in humans.

A reversible inhibitor of Lp-PLA2 (IC₅₀ = 0.25 nM) that produces sustained inhibition of plasma Lp-PLA2 activity in humans.

A TZD that increases the sensitivity of cells to insulin, stimulating insulin-induced PI3K activity at submicromolar concentrations increases insulin effectiveness in obese NIDDM subjects promotes adipocyte differentiation by up-regulating the

A TZD that increases the sensitivity of cells to insulin, stimulating insulin-induced PI3K activity at submicromolar concentrations increases insulin effectiveness in obese NIDDM subjects promotes adipocyte differentiation by up-regulating the

A TZD that increases the sensitivity of cells to insulin, stimulating insulin-induced PI3K activity at submicromolar concentrations increases insulin effectiveness in obese NIDDM subjects promotes adipocyte differentiation by up-regulating the

A TZD that increases the sensitivity of cells to insulin, stimulating insulin-induced PI3K activity at submicromolar concentrations increases insulin effectiveness in obese NIDDM subjects promotes adipocyte differentiation by up-regulating the

A receptor antagonist acting at the muscarinic receptors (Ki = 5.5, 47, 0.84, 8.6, and 2.3 nM for M1 through M5, respectively) effective in treating problems related to the lower urinary tract.